Cabaletta Bio Stock Today
| CABA Stock | USD 1.67 0.01 0.60% |
PerformanceOK
| Odds Of DistressBelow Average
|
Cabaletta Bio is trading at 1.67 as of the 19th of July 2025, a 0.6 percent decrease since the beginning of the trading day. The stock's open price was 1.68. Cabaletta Bio has about a 35 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of October 2019 | Category Healthcare | Classification Health Care |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. The company has 89.94 M outstanding shares of which 5.61 M shares are currently shorted by private and institutional investors with about 1.92 trading days to cover. More on Cabaletta Bio
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cabaletta Stock Highlights
| President Technology | Gwendolyn Binder | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCabaletta Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cabaletta Bio's financial leverage. It provides some insight into what part of Cabaletta Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cabaletta Bio (CABA) is traded on NASDAQ Exchange in USA. It is located in 2929 Arch Street, Philadelphia, PA, United States, 19104 and employs 163 people. Cabaletta Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 150.2 M. Cabaletta Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 89.94 M outstanding shares of which 5.61 M shares are currently shorted by private and institutional investors with about 1.92 trading days to cover.
Cabaletta Bio currently holds about 96.81 M in cash with (88.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cabaletta Bio Probability Of Bankruptcy
Ownership AllocationCabaletta Bio holds a total of 89.94 Million outstanding shares. Over half of Cabaletta Bio's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cabaletta Ownership Details
Cabaletta Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Integral Health Asset Management, Llc | 2025-03-31 | 850 K | |
| Acadian Asset Management Llc | 2025-03-31 | 682.7 K | |
| Ubs Group Ag | 2025-03-31 | 490.2 K | |
| T. Rowe Price Associates, Inc. | 2025-03-31 | 489.3 K | |
| Fred Alger Management, Llc | 2025-03-31 | 477.2 K | |
| Two Sigma Advisers, Llc | 2025-03-31 | 471.5 K | |
| Superstring Capital Management Lp | 2025-03-31 | 459 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 434.4 K | |
| Nuveen, Llc | 2025-03-31 | 434.4 K | |
| T. Rowe Price Investment Management,inc. | 2025-03-31 | 4 M | |
| Adage Capital Partners Gp Llc | 2025-03-31 | 3.6 M |
Cabaletta Bio Historical Income Statement
Cabaletta Stock Against Markets
Cabaletta Bio Corporate Management
| PharmD MBA | SVP International | Profile | |
| Samik MD | Chief Officer | Profile | |
| Aimee MD | CoFounder Board | Profile | |
| Arun MD | Chief Officer | Profile | |
| Anup MBA | Chief Officer | Profile | |
| SPHR CCP | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.